96 related articles for article (PubMed ID: 9525741)
1. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.
Hamilton M; Wolfman A
Oncogene; 1998 Mar; 16(11):1417-28. PubMed ID: 9525741
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effect of monoclonal antibody PD4 on Ha-ras transformed cells Rat3-3].
Yin WN
Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):82-6. PubMed ID: 1879298
[TBL] [Abstract][Full Text] [Related]
3. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 1 alpha mediated inhibition of myogenic terminal differentiation: increased sensitivity of Ha-ras transformed cultures.
Harrington MA; Daub R; Song A; Stasek J; Garcia JG
Cell Growth Differ; 1992 Apr; 3(4):241-8. PubMed ID: 1325182
[TBL] [Abstract][Full Text] [Related]
5. The antisense c-Ha-ras oligodeoxynucleotides inhibit the proliferation of the gastrocarcinoma-DNA-transformed rat 3-3 cells and reduce the p21 expression of the cells.
Xu Y; Deng GR; Liang YY; Li C
Sci China B; 1991 Jan; 34(1):35-41. PubMed ID: 2015062
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of Ha-ras(val12) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha.
Chang MY; Won SJ; Yang BC; Jan MS; Liu HS
Exp Cell Res; 1999 May; 248(2):589-98. PubMed ID: 10222151
[TBL] [Abstract][Full Text] [Related]
7. [The characteristics of the regulation of the cellular proliferation of embryonic rat fibroblasts transformed by E1A+c-Ha-ras oncogenes].
Blagosklonnyĭ MV; Darieva ZA; Pospelova TV
Vopr Onkol; 1991; 37(3):303-10. PubMed ID: 2031324
[TBL] [Abstract][Full Text] [Related]
8. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.
Vasseur S; Malicet C; Calvo EL; Labrie C; Berthezene P; Dagorn JC; Iovanna JL
Mol Cancer; 2003 Mar; 2():19. PubMed ID: 12685932
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Lozano J; Xing R; Cai Z; Jensen HL; Trempus C; Mark W; Cannon R; Kolesnick R
Cancer Res; 2003 Jul; 63(14):4232-8. PubMed ID: 12874031
[TBL] [Abstract][Full Text] [Related]
11. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
12. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
13. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase.
Adler V; Bowne W; Michl J; Sookraj KA; Ikram K; Pestka S; Izotova L; Zenilman M; Friedman FK; Qu Y; Pincus MR
Ann Clin Lab Sci; 2008; 38(1):47-56. PubMed ID: 18316782
[TBL] [Abstract][Full Text] [Related]
14. Regulation of myeloid cell growth by distinct effectors of Ras.
Matsuguchi T; Kraft AS
Oncogene; 1998 Nov; 17(21):2701-9. PubMed ID: 9840934
[TBL] [Abstract][Full Text] [Related]
15. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
16. TC21 and Ras share indistinguishable transforming and differentiating activities.
Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras.
Kawada M; Fukazawa H; Mizuno S; Uehara Y
Biochem Biophys Res Commun; 1997 Feb; 231(3):735-7. PubMed ID: 9070883
[TBL] [Abstract][Full Text] [Related]
18. Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin.
Chang MY; Jan MS; Won SJ; Liu HS
Biochem Biophys Res Commun; 1998 Jul; 248(1):62-8. PubMed ID: 9675086
[TBL] [Abstract][Full Text] [Related]
19. Activation of p21ras is not sufficient to ensure a complete G1 phase of the cell division cycle in mouse fibroblasts.
Gaben AM; Saucier C; Bedin M; Barbu V; Courilleau D; Bon-Hoa DH; Mester J
Oncogene; 1996 Nov; 13(10):2113-20. PubMed ID: 8950978
[TBL] [Abstract][Full Text] [Related]
20. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells.
Cheng G; Meinkoth JL
Oncogene; 2001 Nov; 20(50):7334-41. PubMed ID: 11704863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
